Biovica strengthens the management team

Biovica, active in cancer diagnostics, today announced that the company has strengthened the management team with Helle Fisker as new commercial manager and Joakim Arwidson as new quality and regulatory manager.

2021-04-29T09:00:00+02:00April 29th, 2021 09:00|

Biovica förstärker ledningsgruppen

Biovica, verksamt inom cancerdiagnostik, meddelade idag att bolaget har förstärkt ledningsgruppen med Helle Fisker som ny kommersiell chef och Joakim Arwidson som ny kvalitets- och regulatorisk chef.

2021-04-29T09:00:00+02:00April 29th, 2021 09:00|

DiviTum®TKa budget impact model results show potential for savings in cost of care

Biovica, active in cancer diagnostics, today announced that the results from a budget impact model of monitoring with DiviTum®TKa can give savings of up to three times the extra spend relative to current management. The results will be presented at the leading health economics and outcomes research conference, ISPOR 2021 in May.

2021-04-23T06:30:00+02:00April 23rd, 2021 06:30|

Biovica’s DiviTumTKa prognostic for long-term outcome

Biovica, active in cancer diagnostics, today announced that the results from the breast cancer study PROMIX at Karolinska University Hospital is published in the scientific journal ESMO Open. The study showed that testing for TKa levels during early treatment is prognostic for the long-term outcome of preoperative chemotherapy.

2021-03-11T10:10:00+01:00March 11th, 2021 10:10|

Biovicas DiviTumTKa förutsäger utfall på lång sikt

Biovica, aktivt inom cancerdiagnostik, meddelade idag att resultaten från bröstcancerstudien PROMIX vid Karolinska universitetssjukhuset publiceras i den vetenskapliga tidskriften ESMO Open. Studien visar att TKa-nivåer tidigt under en behandling kan förutsäga det långsiktiga resultatet av preoperativa cellgifter.

2021-03-11T10:10:00+01:00March 11th, 2021 10:10|

Biovicas DiviTum®TKa i studie av tidig behandlingsresistens

DiviTum®TKa har valts ut för att ingå i den nya prospektiva kliniska studien TIRESIAS, i syfte att undersöka om DiviTum®TKa kan användas för att tidigt identifiera behandlingsresistens mot en CDK4/6-hämmare i kombination med en aromatashämmare vid behandling av bröstcancer.

2021-01-18T07:00:00+01:00January 18th, 2021 07:00|

Biovica’s DiviTum®TKa in early treatment resistance trial

DiviTum®TKa has been selected to be included in the new prospective clinical study TIRESIAS, with the aim of investigating if DiviTum®TKa can be used to identify early resistance to treatment by a CDK4/6 inhibitor in combination with an aromatase inhibitor in breast cancer patients.

2021-01-18T07:00:00+01:00January 18th, 2021 07:00|